The future of ophthalmic topical drug delivery is easy-to-use micro-dosing
EYE-GO is a pre-revenue MedTech company developing a game-changing delivery system for eye care treatment: MistGo
The future of ophthalmic topical drug delivery is easy-to-use micro-dosing
EYE-GO is a pre-revenue MedTech company developing a game-changing delivery system for eye care treatment: MistGo
The future of ophthalmic topical drug delivery is easy-to-use micro-dosing
EYE-GO is a pre-revenue MedTech company developing a game-changing delivery system for eye care treatment: MistGo
It is time to eliminate the flaws with dropper bottle
The way people take eye drops has hardly changed the last century.
Eyedropper bottles are difficult to use and overmedicate the eye simple due to the size of a drop.
See EYE-GO’s one-pagers on micro-dosing and user test in the news section.
It is time to eliminate the flaws with dropper bottle
The way people take eye drops has hardly changed the last century.
Eyedropper bottles are difficult to use and overmedicate the eye simple due to the size of a drop.
See EYE-GO’s one-pagers on micro-dosing and user test in the news section.
It is time to eliminate the flaws with dropper bottle
The way people take eye drops has hardly changed the last century.
Eyedropper bottles are difficult to use and overmedicate the eye simple due to the size of a drop.
See EYE-GO’s one-pagers on micro-dosing and user test in the news section.
MistGo® is a user-friendly,superior alternative to conventional eye drops
EYE-GO has developed a delivery system designed to help patients administer their eye medication in a more precise and friendly way
MistGo® is a user-friendly,superior alternative to conventional eye drops
EYE-GO has developed a delivery system designed to help patients administer their eye medication in a more precise and friendly way
MistGo® is a user-friendly,superior alternative to conventional eye drops
EYE-GO has developed a delivery system designed to help patients administer their eye medication in a more precise and friendly way
Only a fraction of patients achieves the full health outcome of treatment due to imperfections with current eye dop bottles
MistGo® helps patients stay well-medicated
Only a fraction of patients achieves the full health outcome of treatment due to imperfections with current eye dop bottles
MistGo® helps patients stay well-medicated
Only a fraction of patients achieves the full health outcome of treatment due to imperfections with current eye dop bottles
MistGo® helps patients stay well-medicated
EYE-GO is a Danish pre-revenue MedTech company aiming to improve the quality of life of people dependent on eye medication by offering a highprecision micro-dosing ocular delivery system mitigating the imperfections with current eye drop bottles: MistGo®
EYE-GO has an experienced team, a versatile board of directors comprising, and a supportive circle of owners.
EYE-GO is a Danish pre-revenue MedTech company aiming to improve the quality of life of people dependent on eye medication by offering a highprecision micro-dosing ocular delivery system mitigating the imperfections with current eye drop bottles: MistGo®
EYE-GO has an experienced team, a versatile board of directors comprising, and a supportive circle of owners.
EYE-GO is a Danish pre-revenue MedTech company aiming to improve the quality of life of people dependent on eye medication by offering a highprecision micro-dosing ocular delivery system mitigating the imperfections with current eye drop bottles: MistGo®
EYE-GO has an experienced team, a versatile board of directors comprising, and a supportive circle of owners.
MEET EYE-GO’S BOARD OF DIRECTORS
Christian Stig Møller
Chairman of the Board
See info
Jacob Dyhr Jensen
Board Member
See info
Ole Feddersen
Board Member
See info
Kim Tosti
Board Member
See info
Morten Nielsen
Board memeber
See info
MEET EYE-GO’S BOARD OF DIRECTORS
Christian Stig Møller
Chairman of the Board
See info
Jacob Dyhr Jensen
Board Member
See info
Ole Feddersen
Board Member
See info
Kim Tosti
Board Member
See info
Morten Nielsen
Board memeber
See info
MEET EYE-GO’S BOARD OF DIRECTORS
Christian Stig Møller
Chairman of the Board
See info
Jacob Dyhr Jensen
Board Member
See info
Ole Feddersen
Board Member
See info
Kim Tosti
Board Member
See info
Morten Nielsen
Board memeber
See info
MEET EYE-GO’S ADVISORS
Miriam Kolko
Scientific Advisor
See info
Steffen Heegard
Scientific Advisor
See info
Marie Gunroth Troili
Commercial Advisor
See info
Dave LeCause
Commercial Advisor
See info
Arnaud Magnier
Commercial Advisor
See info
Geert Nygaard
Commercial Advisor
See info
MEET EYE-GO’S ADVISORS
Miriam Kolko
Scientific Advisor
See info
Steffen Heegard
Scientific Advisor
See info
Marie Gunroth Troili
Commercial Advisor
See info
Dave LeCause
Commercial Advisor
See info
Arnaud Magnier
Commercial Advisor
See info
Geert Nygaard
Commercial Advisor
See info
MEET EYE-GO’S ADVISORS
Miriam Kolko
Scientific Advisor
See info
Steffen Heegard
Scientific Advisor
See info
Marie Gunroth Troili
Commercial Advisor
See info
Dave LeCause
Commercial Advisor
See info
Arnaud Magnier
Commercial Advisor
See info
Geert Nygaard
Commercial Advisor
See info
MistGo® – the future of eye-treatmentsasasa
MistGo® – the future of eye-treatmentsasasa
MistGo® – the future of eye-treatmentsasasa
MistGo® is a user-friendly, superior alternative to conventional eye drops
-
Micro dosing ability & precision
Optimal dose. Precise instillation. Every time.
-
Ease of use and comfort for patient
Easy and comfortable to use for all patients
-
Risk of cross contamination
Avoids cross contamination or trauma in the eye
-
Preservative free drug compatibility
Compatible with preservative free substances
MistGo® is a user-friendly, superior alternative to conventional eye drops
-
Micro dosing ability & precision
Optimal dose. Precise instillation. Every time.
-
Ease of use and comfort for patient
Easy and comfortable to use for all patients
-
Risk of cross contamination
Avoids cross contamination or trauma in the eye
-
Preservative free drug compatibility
Compatible with preservative free substances
MistGo® is a user-friendly, superior alternative to conventional eye drops
-
Micro dosing ability & precision
Optimal dose. Precise instillation. Every time.
-
Ease of use and comfort for patient
Easy and comfortable to use for all patients
-
Risk of cross contamination
Avoids cross contamination or trauma in the eye
-
Preservative free drug compatibility
Compatible with preservative free substances
Poor installation techniques jeopardizes compliance to treatment
Of the routes to administer drugs to the eye, the topical route is the most used. Unfortunately, the design of the eye drop bottle leads many patients to administer their medication incorrectly.
Studies prove that among glaucoma patients, the proportion of patients using improper technique ranges from 34% to 92%. 7-44% miss the eye completely and 18-80% contaminate the tip of the bottle by contacting the eye or surrounding tissue.
Poor installation techniques jeopardizes compliance to treatment
Of the routes to administer drugs to the eye, the topical route is the most used. Unfortunately, the design of the eye drop bottle leads many patients to administer their medication incorrectly.
Studies prove that among glaucoma patients, the proportion of patients using improper technique ranges from 34% to 92%. 7-44% miss the eye completely and 18-80% contaminate the tip of the bottle by contacting the eye or surrounding tissue.
Poor installation techniques jeopardizes compliance to treatment
Of the routes to administer drugs to the eye, the topical route is the most used. Unfortunately, the design of the eye drop bottle leads many patients to administer their medication incorrectly.
Studies prove that among glaucoma patients, the proportion of patients using improper technique ranges from 34% to 92%. 7-44% miss the eye completely and 18-80% contaminate the tip of the bottle by contacting the eye or surrounding tissue.
Studies show that micro-dosing is as safe and efficacious as normal eye-drops
Medicating with an eye dropper result in a drop containing 30-50 μl which greatly exceeds the physiologic 6-8 μL ocular tear film capacity.
A part of the delivered solution is washed out of the eye, but up to 80% of the dose enters the systemic circulation via transport into surface blood vessels or passage through the nasal lacrimal duct and into the digestive system, leading to an increased risk of systemic adverse events.
Any excess solution remaining in the eye can lead to local adverse events, incl. hypersensitivity reactions to the drug or excipients.
From a biopharmaceutical and economic point of view, the ideal would be to instill smaller volumes of eye medication as they can achieve a maximal tear film concentration with far less systemic absorption.
Studies show that micro-dosing is as safe and efficacious as normal eye-drops
Medicating with an eye dropper result in a drop containing 30-50 μl which greatly exceeds the physiologic 6-8 μL ocular tear film capacity.
A part of the delivered solution is washed out of the eye, but up to 80% of the dose enters the systemic circulation via transport into surface blood vessels or passage through the nasal lacrimal duct and into the digestive system, leading to an increased risk of systemic adverse events.
Any excess solution remaining in the eye can lead to local adverse events, incl. hypersensitivity reactions to the drug or excipients.
From a biopharmaceutical and economic point of view, the ideal would be to instill smaller volumes of eye medication as they can achieve a maximal tear film concentration with far less systemic absorption.
Studies show that micro-dosing is as safe and efficacious as normal eye-drops
Medicating with an eye dropper result in a drop containing 30-50 μl which greatly exceeds the physiologic 6-8 μL ocular tear film capacity.
A part of the delivered solution is washed out of the eye, but up to 80% of the dose enters the systemic circulation via transport into surface blood vessels or passage through the nasal lacrimal duct and into the digestive system, leading to an increased risk of systemic adverse events.
Any excess solution remaining in the eye can lead to local adverse events, incl. hypersensitivity reactions to the drug or excipients.
From a biopharmaceutical and economic point of view, the ideal would be to instill smaller volumes of eye medication as they can achieve a maximal tear film concentration with far less systemic absorption.
MistGo® is designed to micro-dose
MistGo® contains a high-precision micropump, consistently metering a dose of 6 μL, dispensing no excess liquid to irritate the skin, enter systemic circulation or risk adverse events.
The internal geometry of the nozzle is designed to vaporise the drug into a fine mist with a broad impact pattern, coating the entire cornea for optimal absorption (~10-12 mm diameter).
MistGo® is designed to micro-dose
MistGo® contains a high-precision micropump, consistently metering a dose of 6 μL, dispensing no excess liquid to irritate the skin, enter systemic circulation or risk adverse events.
The internal geometry of the nozzle is designed to vaporise the drug into a fine mist with a broad impact pattern, coating the entire cornea for optimal absorption (~10-12 mm diameter).
MistGo® is designed to micro-dose
MistGo® contains a high-precision micropump, consistently metering a dose of 6 μL, dispensing no excess liquid to irritate the skin, enter systemic circulation or risk adverse events.
The internal geometry of the nozzle is designed to vaporise the drug into a fine mist with a broad impact pattern, coating the entire cornea for optimal absorption (~10-12 mm diameter).
Preservative-free eye medication requires sterility in delivery system
Eye drops delivered in a multidose container must maintain sterility of the contents throughout the use period, as microbial keratitis is a
risk for users of topical ophthalmic solutions upon accidental contamination of the product.
Antimicrobial activity is often achieved through the addition of
preservatives – the most frequently used benzalkonium chloride (BAK) – which due to toxicity have deleterious effects on the ocular surface.
Removal of the preservative eliminates preservative-induced complications.
A preservative free eye medication must be dispensed in a delivery system designed to keep the liquid formulation sterile
throughout the treatment period.
Preservative-free eye medication requires sterility in delivery system
Eye drops delivered in a multidose container must maintain sterility of the contents throughout the use period, as microbial keratitis is a
risk for users of topical ophthalmic solutions upon accidental contamination of the product.
Antimicrobial activity is often achieved through the addition of
preservatives – the most frequently used benzalkonium chloride (BAK) – which due to toxicity have deleterious effects on the ocular surface.
Removal of the preservative eliminates preservative-induced complications.
A preservative free eye medication must be dispensed in a delivery system designed to keep the liquid formulation sterile
throughout the treatment period.
Preservative-free eye medication requires sterility in delivery system
Eye drops delivered in a multidose container must maintain sterility of the contents throughout the use period, as microbial keratitis is a
risk for users of topical ophthalmic solutions upon accidental contamination of the product.
Antimicrobial activity is often achieved through the addition of
preservatives – the most frequently used benzalkonium chloride (BAK) – which due to toxicity have deleterious effects on the ocular surface.
Removal of the preservative eliminates preservative-induced complications.
A preservative free eye medication must be dispensed in a delivery system designed to keep the liquid formulation sterile
throughout the treatment period.
MistGo® – can be used for medication both with and without preservatives
MistGo® is airtight and designed to maintain sterility in the following way:
- Integrates a collapsible multilayer cartridge obviating air ventilation.
No backflow of (contaminated) air requiring filtering. - The liquid is sealed off from the environment using nonpermeable
materials. Several barriers are established to separate the liquid
from the environment. - The system enables pressurized air to both create the mist and
completely clean the outlet nozzle chamber after dispensing. The
liquid column is broken, and no liquid is left for later microbiocidal
contamination. - An eye interface protects the nozzle from contamination caused by
user contact, and a lid helps protect the dosing chamber during
storage between use.
MistGo® – can be used for medication both with and without preservatives
MistGo® is airtight and designed to maintain sterility in the following way:
- Integrates a collapsible multilayer cartridge obviating air ventilation.
No backflow of (contaminated) air requiring filtering. - The liquid is sealed off from the environment using nonpermeable
materials. Several barriers are established to separate the liquid
from the environment. - The system enables pressurized air to both create the mist and
completely clean the outlet nozzle chamber after dispensing. The
liquid column is broken, and no liquid is left for later microbiocidal
contamination. - An eye interface protects the nozzle from contamination caused by
user contact, and a lid helps protect the dosing chamber during
storage between use.
MistGo® – can be used for medication both with and without preservatives
MistGo® is airtight and designed to maintain sterility in the following way:
- Integrates a collapsible multilayer cartridge obviating air ventilation.
No backflow of (contaminated) air requiring filtering. - The liquid is sealed off from the environment using nonpermeable
materials. Several barriers are established to separate the liquid
from the environment. - The system enables pressurized air to both create the mist and
completely clean the outlet nozzle chamber after dispensing. The
liquid column is broken, and no liquid is left for later microbiocidal
contamination. - An eye interface protects the nozzle from contamination caused by
user contact, and a lid helps protect the dosing chamber during
storage between use.
MistGo® has a large performance window and is customizable to many drugs – including the sticky ones
Parameters in MistGo® can be customized to suit the needs of individual drugs including those with high viscosity enabling the delivery system to perform optimally for liquids for a variety of both RX (prescription) and OTC (over the counter) medicines
- Micro-dosing: a high-precision pump consistently meters a dose of 6 μL, dispensing no excess liquid to irritate the skin or enter systemic circulation.
- Delivery time: the dose is fully delivered before the eye can blink
- Gentle: the internal geometry of the nozzle is optimized to vaporize the liquid into a fine mist of micro droplets, which feels comfortable and soothing in the eye compared to a single dense drop
- Precision: the entire mist is delivered precisely within the target area: the cornea (11mm diameter when the eye is fully open)
MistGo® has a large performance window and is customizable to many drugs – including the sticky ones
Parameters in MistGo® can be customized to suit the needs of individual drugs including those with high viscosity enabling the delivery system to perform optimally for liquids for a variety of both RX (prescription) and OTC (over the counter) medicines
- Micro-dosing: a high-precision pump consistently meters a dose of 6 μL, dispensing no excess liquid to irritate the skin or enter systemic circulation.
- Delivery time: the dose is fully delivered before the eye can blink
- Gentle: the internal geometry of the nozzle is optimized to vaporize the liquid into a fine mist of micro droplets, which feels comfortable and soothing in the eye compared to a single dense drop
- Precision: the entire mist is delivered precisely within the target area: the cornea (11mm diameter when the eye is fully open)
MistGo® has a large performance window and is customizable to many drugs – including the sticky ones
Parameters in MistGo® can be customized to suit the needs of individual drugs including those with high viscosity enabling the delivery system to perform optimally for liquids for a variety of both RX (prescription) and OTC (over the counter) medicines
- Micro-dosing: a high-precision pump consistently meters a dose of 6 μL, dispensing no excess liquid to irritate the skin or enter systemic circulation.
- Delivery time: the dose is fully delivered before the eye can blink
- Gentle: the internal geometry of the nozzle is optimized to vaporize the liquid into a fine mist of micro droplets, which feels comfortable and soothing in the eye compared to a single dense drop
- Precision: the entire mist is delivered precisely within the target area: the cornea (11mm diameter when the eye is fully open)
Let’s improve your Patient Pharma company value proposition and increase patients’ quality of life
Contact EYE-GO
Patient
- Reduced dosing uncertainty
- Reduced systemic exposure
- Reduced side effects
- Reduced stigmatization
- Better usability & convenience
- Precise drug administration
- Better disease management
- Higher patient quality of life
- sasas
- asas
- asas
Pharma Company
- Better value selling
- More patient-centric
- More versatile user/use profile
- Reduced stigmatization
- Higher clinical outcome
- Higher brand loyalty
- Extended product life cycle
- Realize full business potential
Let’s improve your Patient Pharma company value proposition and increase patients’ quality of life
Contact EYE-GO
Patient
- Reduced dosing uncertainty
- Reduced systemic exposure
- Reduced side effects
- Reduced stigmatization
- Better usability & convenience
- Precise drug administration
- Better disease management
- Higher patient quality of life
- sasas
- asas
- asas
Pharma Company
- Better value selling
- More patient-centric
- More versatile user/use profile
- Reduced stigmatization
- Higher clinical outcome
- Higher brand loyalty
- Extended product life cycle
- Realize full business potential
Let’s improve your Patient Pharma company value proposition and increase patients’ quality of life
Contact EYE-GO
Patient
- Reduced dosing uncertainty
- Reduced systemic exposure
- Reduced side effects
- Reduced stigmatization
- Better usability & convenience
- Precise drug administration
- Better disease management
- Higher patient quality of life
- sasas
- asas
- asas
Pharma Company
- Better value selling
- More patient-centric
- More versatile user/use profile
- Reduced stigmatization
- Higher clinical outcome
- Higher brand loyalty
- Extended product life cycle
- Realize full business potential
Get in touch with us
Contact us today to learn more about how MistGo® can help your
ophthalmic therapeutic treatment perform to its best.
Get in touch with us
Contact us today to learn more about how MistGo® can help your
ophthalmic therapeutic treatment perform to its best.
Get in touch with us
Contact us today to learn more about how MistGo® can help your
ophthalmic therapeutic treatment perform to its best.